Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

If you need assistance at any time, please press star zero, and a member of our team will be happy to help you. Thank you. © transcript Emily Beynon ¶¶ 🎵 🎵 Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. ¦ ¦ ¶¶ ¶¶ ¶¶ Thank you. © transcript Emily Beynon Hello and welcome everyone joining today's Cognition Therapeutics fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Mike Moyer with LifeSci Advisors. Please go ahead. Thank you, operator, and good morning, everyone. Welcome to Cognitions Therapeutics' fourth quarter and year-end 2025 results conference call. With me today are Lisa Ricciardi, President and Chief Executive Officer, John Doyle, Chief Financial Officer, and Dr. Tony Caggiano, Chief Medical Officer. This morning the company issued a press release detailing its 2025 fourth quarter and year-end results. We encourage everyone to read this morning's press release as well as Cognition's annual report on Form 10-K, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for 30 days. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We cau...